The company’s performance was anchored by a 9% rise in medical device sales, bolstered by double-digit growth in electrophysiology and solid returns from its diabetes care portfolio. While GAAP diluted earnings per share hit $0.53, adjusted figures—which strip out specific acquisition and legal costs—reached $1.31. Chairman and CEO Robert B. Ford noted the firm’s current momentum, expressing expectations for accelerated sales and earnings growth throughout the remainder of the year.
Abbott Lifts Profit Outlook After Strong Second Quarter
Abbott Laboratories reported a 13% increase in second-quarter sales and raised its full-year earnings guidance, signaling confidence in the company's growth trajectory. The medical device and diagnostics giant now projects adjusted diluted earnings per share between $5.45 and $5.60 for 2026, up from its previous forecast.
Operational milestones in the quarter included the completion of enrollment for the TECTONIC U.S. pivotal trial, which tests a new coronary intravascular lithotripsy system, and the receipt of a CE Mark for the Libre Duo glucose-ketone sensor. Additionally, Abbott returned $2.1 billion to shareholders via dividends and share repurchases, maintaining its status in the S&P 500 Dividend Aristocrats Index with its 410th consecutive quarterly payout.
Comments (0)
No comments yet. Be the first!